Amylyx Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Amylyx Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Amylyx Pharmaceuticals Inc
Access all reports
Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company's research and product development primarily target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to slow disease progression and improve patient outcomes. Amylyx leverages its scientific expertise in neurobiology to create therapies that address the underlying mechanisms of these diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Amylyx Pharmaceuticals Inc
M&A Announcement
Amylyx Pharmaceuticals Inc
M&A Announcement
Amylyx Pharmaceuticals Inc
Latest articles
What Investors Get Wrong: Chris Mayer on Dividends, Noise, and the Power of Reinvestment
Chris Mayer challenges investor myths on dividends, market noise, and the reinvestment edge. A deep dive into long-term thinking.
29 Nov 2024
Evolution: The Live Casino Juggernaut
With ~49% CAGR since its 2015 IPO, 60%+ EBIT margin, and global dominance in live casino, the story of Evolution is truly one for the books.
22 Nov 2024
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
Ticker symbol
AMLX
Country
🇺🇸 United States